Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mi:Rna Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being handled by 1 distinct examiner within 1 distinct art unit, reflecting a highly concentrated prosecution effort. For a company in the biotech sector, this suggests a focus on a specific core technology or a single patent application. The concentration of 1 pending office action in 1 distinct art unit simplifies the administrative burden of tracking multiple applications across different departments.
DAUNER, JOSEPH G is the busiest examiner for the company, with 1 busiest examiner pending action under their review. Because this 1 action is the only one currently pending, the company's immediate patenting success relies entirely on the interaction with this 1 distinct examiner. The focus on 1 distinct art unit means that the prosecution strategy does not need to account for the varying examination styles found across different pharmaceutical divisions. This allows the company to tailor its legal arguments specifically for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044283 | BIOMARKERS FOR DIAGNOSING A DISEASE SUCH AS HEART OR CARDIOVASCULAR DISEASE | DAUNER, JOSEPH G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044283 | BIOMARKERS FOR DIAGNOSING A DISEASE SUCH AS HEART OR CARDIOVASCULAR DISEASE | DAUNER, JOSEPH G | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044283 | BIOMARKERS FOR DIAGNOSING A DISEASE SUCH AS HEART OR CARDIOVASCULAR DISEASE | DAUNER, JOSEPH G | 1682 | §101§112DP | Non-Final OA | — | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial